medRxiv preprint doi: https://doi.org/10.1101/2024.02.09.24302604; this version posted February 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

Vitreous fluid-isolated DNA for the genetic analysis of 1

primary uveal melanoma: a proof-of-concept study 2

3	Authors
•	

- 4 R.J. Nell¹
- 5 M. Versluis¹
- 6 N.V. Menger¹
- 7 M.C. Gelmi¹
- 8 T.H.K. Vu¹
- 9 R.M. Verdijk^{2,3}
- G.P.M. Luyten¹ 10
- 11 M.J. Jager¹
- 12 P.A. van der Velden^{1*}
- 13
- 14 ¹ Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
- 15 ² Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
- 16 ³ Department of Pathology, Section Ophthalmic Pathology, Erasmus MC University Medical
- 17 Center, Rotterdam, the Netherlands.
- 18
- 19 * Corresponding author, Department of Ophthalmology, Leiden University Medical Center,
- 20 PO Box 9600, 2300 RC Leiden, The Netherlands.
- 21

22 Acknowledgements

- 23 This study was supported by the European Union's Horizon 2020 research and innovation
- 24 program under grant agreement number 667787 (UM Cure 2020, R.J. Nell and N.V.
- 25 Menger). The authors thank the UM Cure 2020 consortium partners and patient
- 26 organisations for their helpful discussions regarding this research project.

27 Abstract

28 Background

29 Uveal melanoma is an aggressive ocular malignancy. Early molecular characterisation of

- 30 primary tumours is crucial to identify those at risk of metastatic dissemination. Although
- 31 tumour biopsies are being taken, liquid biopsies of ocular fluids may form a less invasive but
- 32 relatively unexplored alternative. In this study, we aim to evaluate the DNA content of
- 33 vitreous fluid from eyes with a uveal melanoma to obtain molecular information from the
- 34 tumour.
- 35

36 Methods

37 DNA was isolated from 65 vitreous fluid samples from enucleated eyes with a uveal

38 melanoma and studied using digital PCR. Primary and additional driver mutations (in *GNAQ*,

39 GNA11, PLCB4, CYSLTR2, BAP1, SF3B1 and EIF1AX) were investigated using accustomed

40 targeted and drop-off assays. The copy numbers of chromosome 3p and 8q were measured

- 41 using multiplex and single-nucleotide polymorphism-based assays. Our findings were
- 42 compared to the molecular profile of matched primary tumours and to the clinicopathological
- 43 tumour characteristics.
- 44

45 Results

46 Almost all (63/65) vitreous fluids had measurable levels of DNA, but melanoma-cell derived

47 DNA (containing the primary driver mutation) was detected in 39/65 samples (median

48 proportion 18%, range 0.2%-94%) and was associated with a larger tumour prominence, but

49 not with any of the molecular tumour subtypes. Among the vitreous fluids with melanoma-cell

- 50 derived DNA, not all samples harboured (analysable) other mutations or had sufficient
- 51 statistical power to measure copy numbers. Still, additional mutations in *BAP1*, *SF3B1* and
- 52 *EIF1AX* were detected in 13/15 samples and chromosome 3p and 8q copy numbers
- 53 matched the primary tumour in 19/21 and 18/20 samples, respectively. Collectively, a
- 54 clinically-relevant molecular classification of the primary tumour could be inferred from 27/65
- 55 vitreous fluids.
- 56

57 Discussion

58 This proof-of-concept study shows that substantial amounts of DNA could be detected in

- 59 vitreous fluids from uveal melanoma patients, including melanoma-cell derived DNA in 60%
- 60 of the samples. Prognostically-relevant genetic alterations of the primary tumour could be
- 61 identified in 42% of the patients. A follow-up study is needed to evaluate our approach in a
- 62 prospective clinical context.

Page 2 of 24

63 Introduction

64 Uveal melanoma is a rare, aggressive intraocular tumour originating from malignantly-

transformed melanocytes in the iris, ciliary body or choroid (**Figure 1**). The majority of uveal

- 66 melanomas are located in the relatively inconspicuous and inaccessible posterior segment of
- the eye [1]. Consequently, primary tumours can be large upon first detection and
- 68 (micro)metastases may occur before first treatment [2, 3]. For that reason, early and
- adequate identification and characterisation of primary uveal melanomas is crucial to prevent
- 70 tumour progression and ameliorate patient outcome.
- 71

72 Over the past decades, prognostically-relevant molecular tumour subtypes have been

identified based on the genetic alterations present in the primary uveal melanoma. Tumours

74 with *EIF1AX* mutations are generally copy number stable and have the best prognosis with

the lowest risk of early metastatic dissemination [4, 5]. *SF3B1*-mutant tumours often present

with additional copies of chromosome 8q and are associated with an intermediate prognosis
with relatively late metastases [4, 6-8]. Uveal melanomas with a loss of chromosome 3p and

- a *BAP1* mutation, typically also showing chromosome 8q copy number increases, have the
 poorest prognosis [9, 10].
- 80

81 Primary uveal melanoma is usually treated by local, eye-preserving procedures

82 (brachytherapy, proton beam therapy) or a complete surgical removal of the eye

83 (enucleation) [1]. In case of the latter, tumour tissue is readily available for molecular

84 analysis, and such analysis is usually offered to all enucleated patients. For non-enucleated

85 patients, however, an additional tumour biopsy is required to obtain a molecular profile of the

86 melanoma. While intra-ocular fine-needle aspirate tumour biopsies are being taken routinely

in a number of clinics, the procedure is relatively invasive and remains accompanied by

various risks [11, 12]. A less invasive (outpatient) biopsy procedure would allow more

89 patients to have a personalised molecular diagnosis and prognosis. Moreover, those with an

90 increased risk of metastatic dissemination may be offered a more intense follow-up

screening program, and could possibly benefit from earlier detection of metastasis.

92 Additionally, knowledge about the molecular profile of the primary tumour has been positively

associated with various aspects of psychosocial well-being [13] and might be of (future)

94 clinical relevance with regard to novel (neo-)adjuvant therapies [5, 14, 15].

95

96 Previously, we introduced digital PCR assays to analyse the key genetic alterations in uveal

- 97 melanoma to quantify the intratumour heterogeneity in bulk tumour specimens [16-20].
- 98 Digital PCR can also be used for the sensitive detection of genetic alterations in scarce DNA

- 99 samples, such as liquid biopsies (i.e. samples of body fluids such as blood or serum, urine or
- 100 aspirates) [21]. In this study (Figure 1), we isolate DNA from 65 vitreous fluid samples
- 101 obtained from enucleated eyes with a uveal melanoma. These samples are analysed for
- 102 mutations in GNAQ, GNA11, PLCB4, CYSLTR2, EIF1AX, SF3B1 and BAP1, and copy
- 103 number alterations (CNAs) affecting chromosomes 3p and 8q. Next, our findings are
- 104 compared to the molecular profile of matched primary tumours and to the clinicopathological
- 105 tumour characteristics. Collectively, this study forms the proof-of-concept for a
- 106 comprehensive characterisation of the DNA content of the vitreous as a potential liquid
- 107 biopsy for uveal melanoma patients to identify those at high risk of developing metastases.

108 Materials and methods

109 Vitreous fluid sample collection and DNA isolation

Vitreous fluid samples were collected from 65 enucleated eyes with a uveal melanoma as part of the biobank of the Department of Ophthalmology, Leiden University Medical Center (LUMC). Samples had been isolated by syringe suction directly after opening the enucleated eye, and stored at -80 °C. This study was approved by the LUMC Biobank Committee and Medisch Ethische Toetsingscommissie under numbers B14.003/SH/sh and B20.026/KB/kb.

115

116 Total DNA was isolated from 100-200 uL vitreous fluid, using the Quick-cfDNA Serum &

- 117 Plasma Kit (Zymo Research, Irvine, USA) and eluted in 35 uL DNA elution buffer (Zymo),
- following the manufacturer's instructions. From all samples, the matched primary uveal
- 119 melanoma was analysed in our recent study using digital PCR and targeted DNA and RNA
- sequencing [20]. Clinical and molecular information of all samples is summarised in
- 121 Supplementary Table 1.
- 122

123 Digital PCR experiments

124 All digital PCR experiments were carried out using the QX200 Droplet Digital PCR System

- 125 (Bio-Rad Laboratories, Hercules, USA) using the assays and following the protocols
- described earlier [16-20, 22]. Typically, 3.5 uL isolated vfDNA was analysed in a single 22 uL
- 127 experiment, using 11 uL ddPCR[™] Supermix for Probes (No dUTP, Bio-Rad) and primers
- and FAM- or HEX-labelled probes in final concentrations of 900 and 250 nM for duplex
- 129 experiments, or optimised concentrations for multiplex experiments. Assay details are
- 130 described in our recent study [20].
- 131

132 All PCR mixtures were partitioned into 20,000 droplets using the AutoDG System (Bio-Rad).

133 Next, a PCR protocol was performed in a T100 Thermal Cycler (Bio-Rad): 10 minutes at 95

134 °C; 30 seconds at 94 °C and 1 minute at 55 °C, 58 °C or 60 °C for 40 cycles; 10 minutes at

- 135 98 °C; cooling at 12 °C for up to 48 hours, until droplet reading. Ramp rate was set to 2
- 136 °C/second for all steps.
- 137
- 138 Reading of the droplets was performed using the QX200 Droplet Reader (Bio-Rad). The raw
- results of the digital PCR experiments were acquired using *QuantaSoft* (version 1.7.4, Bio-
- 140 Rad) and imported and analysed in the online digital PCR management and analysis
- 141 application *Roodcom WebAnalysis* (version 2.0, available via
- 142 <u>https://webanalysis.roodcom.nl</u>).

143	
144	First of all, the $G\alpha_q$ signalling mutations (in GNAQ, GNA11, CYSLTR2 and PLCB4) were
145	analysed in duplex experiments and the measured concentrations (listed between square
146	brackets) of the mutant and wild-type alleles were used to calculate the total vfDNA
147	concentrations and melanoma-cell derived vfDNA fractions:
148	
149	total vfDNA concentration = [mutation] + [wildtype]
150	
151	melanoma-cell derived vfDNA fraction = 2 · [mutation] [mutation] + [wildtype]
152	
153	Additional BSE mutations in <i>BAP1</i> , <i>SF3B1</i> and <i>EIF1AX</i> were interpreted in a qualitative
154	manner only.
155	
156	CNAs were measured via two different approaches [19]. Following the classic approach,
157	copy number values were calculated based on the measured concentrations of a DNA target
158	on chromosome $3p$ (<i>PPARG</i>) and $8q$ (<i>PTK2</i>), and a reference gene on chromosome $5p$
159	(<i>TERT</i>) or 14q (<i>TTC5</i>) assumed to be stable:
160	
161	copy number value = 2 · [target]
161 162	copy number value = 2 · [[target] [reference]
161 162 163	copy number value = $2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the
161 162 163 164	copy number value = $2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a
161 162 163 164 165	copy number value = $2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP:
161 162 163 164 165 166	copy number value = $2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP:
161 162 163 164 165 166	copy number value = $2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP:
161 162 163 164 165 166 167	copy number value = $2 \cdot \frac{[\text{target}]}{[\text{reference}]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: copy number value = $1 + \frac{[\text{var}_1]}{[\text{var}_2]}$
161 162 163 164 165 166 167 168	copy number value = $2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: copy number value = $1 + \frac{[var_1]}{[var_2]}$
161 162 163 164 165 166 167 168 169	$copy number value = 2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: $copy number value = 1 + \frac{[var_1]}{[var_2]}$ In this formula, the SNP variant in the denominator (var ₂) is the one that was assumed to be
161 162 163 164 165 166 167 168 169 170	$copy number value = 2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: $copy number value = 1 + \frac{[var_1]}{[var_2]}$ In this formula, the SNP variant in the denominator (var ₂) is the one that was assumed to be unaltered and copy number stable (i.e. haploid). Analysed SNPs in this study included
161 162 163 164 165 166 167 168 169 170 171	$copy number value = 2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: $copy number value = 1 + \frac{[var_1]}{[var_2]}$ In this formula, the SNP variant in the denominator (var ₂) is the one that was assumed to be unaltered and copy number stable (i.e. haploid). Analysed SNPs in this study included rs6617, rs6976, rs9586, rs1989839, rs1062633 and rs2236947 on chromosome 3p, and
161 162 163 164 165 166 167 168 169 170 171 172 173	$copy number value = 2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: $copy number value = 1 + \frac{[var_1]}{[var_2]}$ In this formula, the SNP variant in the denominator (var ₂) is the one that was assumed to be unaltered and copy number stable (i.e. haploid). Analysed SNPs in this study included rs6617, rs6976, rs9586, rs1989839, rs1062633 and rs2236947 on chromosome 3p, and rs7018178 and rs7843014 on chromosome 8q.
161 162 163 164 165 166 167 168 169 170 171 172 173 174	$copy number value = 2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: $copy number value = 1 + \frac{[var_1]}{[var_2]}$ In this formula, the SNP variant in the denominator (var ₂) is the one that was assumed to be unaltered and copy number stable (i.e. haploid). Analysed SNPs in this study included rs6617, rs6976, rs9586, rs1989839, rs1062633 and rs2236947 on chromosome 3p, and rs7018178 and rs7843014 on chromosome 8q.
 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 	$copy number value = 2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: $copy number value = 1 + \frac{[var_1]}{[var_2]}$ In this formula, the SNP variant in the denominator (var ₂) is the one that was assumed to be unaltered and copy number stable (i.e. haploid). Analysed SNPs in this study included rs6617, rs6976, rs9586, rs1989839, rs1062633 and rs2236947 on chromosome 3p, and rs7018178 and rs7843014 on chromosome 8q. In silico evaluation of digital PCR sensitivity and power prediction To evaluate the statistical power of detecting CNAs in the vfDNA+/UM+ samples. we
 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 	$copy number value = 2 \cdot \frac{[target]}{[reference]}$ Following the SNP-based approach, copy number values were measured using the concentrations of haploid genomic loci var ₁ and var ₂ , representing the two variants of a heterozygous SNP: $copy number value = 1 + \frac{[var_1]}{[var_2]}$ In this formula, the SNP variant in the denominator (var ₂) is the one that was assumed to be unaltered and copy number stable (i.e. haploid). Analysed SNPs in this study included rs6617, rs6976, rs9586, rs1989839, rs1062633 and rs2236947 on chromosome 3p, and rs7018178 and rs7843014 on chromosome 8q. In silico evaluation of digital PCR sensitivity and power prediction To evaluate the statistical power of detecting CNAs in the vfDNA+/UM+ samples, we performed <i>in silico</i> digital PCR simulations using our R library <i>digitalPCRsimulations</i>

- (available via <u>https://github.com/rjnell/digitalPCRsimulations</u>), as described recently [19]. In
 short, for each individual sample, we determined the sensitivity (% of simulated experiments)
 of detecting a chromosomal loss (copy number = 1) or gain (copy number = 3), assuming
 that this alteration is clonally present in the entire vfDNA melanoma-cell population. An
- 181 alteration was considered 'detected' when the obtained copy number was lower or higher
- 182 than 2 and the constructed 99%-confidence interval did not contain 2. The input vfDNA
- 183 concentration and melanoma-cell fraction were based on the initial $G\alpha_q$ mutation and wild-
- type measurements. The total amount of accepted droplets was set to 15,000 and each
- 185 condition was simulated up to 1,000 times. An experimental setup (classic or SNP-based
- approach) was considered 'underpowered' in samples with a sensitivity <80% when
- 187 analysing a maximum of 45,000 droplets.
- 188

189 Statistical analysis and code availability

- 190 Statistical evaluations in this study were conducted using Spearman's rank correlation
- 191 coefficient, Fisher's exact test, the Mann-Whitney *U* test and the log-rank test. All analyses
- 192 were performed using R version 4.0.3 in RStudio version 1.4.1103. All custom scripts are via
- 193 <u>https://github.com/rjnell/um-vitreous</u>.

194 **Results**

195 DNA composition of vitreous fluid samples assessed by mutant and wild-type $G\alpha_q$

196 $G\alpha_{\alpha}$ signalling mutations at established hotspots in *GNAQ*, *GNA11*, *CYSLTR2* and *PLCB4* 197 are considered the initiating events driving the development of uveal melanoma [18, 23-28]. 198 As they form the most clonal and most common genetic alteration in the primary tumour, they 199 represent a relatively generic marker of the malignant cells that can be used to quantify the 200 abundance of melanoma-cell derived DNA [20]. Based on the exact $G\alpha_{d}$ mutation that was 201 identified earlier in the matched primary tumour [20], we investigated all vitreous fluid DNA 202 (vfDNA) samples using targeted digital PCR for the absolute and relative abundance of 203 mutant and wild-type DNA (Figure 2 and 3A).

204

205 We did not find mutant or wild-type alleles in 2/65 (3%) samples, indicating that these

samples did not contain measurable amounts of vfDNA (**Figure 2**). Wild-type $G\alpha_q$ alleles only

were detected in 24/65 (37%) vitreous fluid samples; these samples were labelled as

208 vfDNA+/UM-, as they had measurable levels of vfDNA but lacked DNA that was derived

from mutant melanoma cells (**Figure 2 and 3A**). Still, they contained up to ~1500 genomic

210 copies per uL vitreous fluid (median 22 genomic copies per uL). In one vfDNA+/UM- patient,

211 the primary uveal melanoma was known to carry two clonally-abundant $G\alpha_q$ signalling

212 mutations (*GNA11* p.R183H and *PLCB4* p.D630N in vfDNA-29), but the vfDNA only

213 contained wild-type *GNA11* and *PLCB4* in comparable concentrations.

214

215 Mutant $G\alpha_q$ alleles were detected in 39/65 (60%) samples, which were labelled as

vfDNA+/UM+ (Figure 2 and 3A). In these samples, the sum of mutant and wild-type allele

concentrations was taken as total vfDNA concentration (median 134 genomic copies per uL).

218 The mutant allele fractions were used to estimate the abundance of melanoma-cell derived

vfDNA, revealing proportions between 0.2% and 94% (median 18%). vfDNA+/UM+ samples

also contained significantly more non-melanoma cell derived vfDNA (i.e. DNA not derived

from uveal melanoma cells, Mann-Whitney U p = 0.011) than vfDNA+/UM- samples (**Figure**

222 **3B**).

223

224 Analysis of additional BSE mutations in *BAP1*, *SF3B1* and *EIF1AX*

225 Besides the generic $G\alpha_q$ mutations, the majority of all uveal melanomas are known to carry

226 an additional 'BSE mutation' in *BAP1*, *SF3B1* or *EIF1AX* [4, 7, 9]. In contrast to the $G\alpha_{\alpha}$

227 mutations, however, only a subset of those BSE mutations can be found at a hotspot

position. In our cohort of primary uveal melanomas from vfDNA+/UM+ patients [20], BAP1

, i

alterations occurred throughout the entire gene, most of the *SF3B1* mutations affected
position p.R625, and *EIF1AX* mutations were found at various positions within the first two
exons of the gene (**Supplementary Table 1**).

232

233 To be able to analyse these diverse BSE mutations, we developed a variety of targeted and 234 generic drop-off digital PCR assays [20]. Hereby, a small number of unique BAP1 alterations, 235 all hotspot mutations in SF3B1 (p.R625C/H), and all mutations in EIF1AX (exon 1 and exon 236 2) could be analysed (Figure 4 and Supplementary Table 1). We now applied these assays 237 in the corresponding cohort of vfDNA+/UM+ samples (n=15). A selection of vfDNA+/UM-238 samples with matched total vfDNA concentrations were measured as negative controls 239 (Figure 4). Based on the known mutational status of the respective primary tumours, EIF1AX 240 mutations were successfully identified in 5/6 vitreous fluid samples, SF3B1 mutations in 5/6 241 samples and BAP1 mutations in 5/5 samples (Figure 2). Two samples (vfDNA-07 and 242 vfDNA-56) carried two BSE mutations, which were both detected in the vfDNA. Of note, the 243 two vitreous fluid samples with undetected BSE mutations (vfDNA-23 and vfDNA-49) had 244 two of the lowest concentrations of $G\alpha_{\alpha}$ mutant alleles within the vfDNA+/UM+ cohort (**Figure** 245 2 and Supplementary Table 1). In total, 13/15 (87%) of the analysed vitreous fluid samples 246 had a measurable BSE mutation matching with the corresponding primary tumour.

247

248 Advanced chromosome 3p and 8q copy number analysis

249 CNAs are usually studied by comparing the absolute abundance of a target of interest to a 250 stable genomic reference (classic approach, Figure 5A) [19]. As an alternative, CNAs may 251 be measured by evaluating the allelic (im)balance between the two variants of a 252 heterozygous SNP on the chromosome of interest (SNP-based approach, Figure 5A). While 253 both SNP variants are equally abundant under healthy conditions, this balance is altered 254 when there is a copy number loss or gain of one of the alleles. Conveniently, a stable 255 genomic reference is not required when using this approach and more precise 256 measurements can be obtained. We recently validated this methodology for detecting 257 chromosome 3p and 8q alterations in uveal melanoma [19]. 258

The precision of digital PCR measurements also depends on the amount of DNA input (limited by the low quantity of our samples) and the number of partitions (i.e. droplets) [19]. A typical digital PCR experiment yields between 10,000 and 20,000 droplets, but this can be increased by repeating the experiment and merging the results into one combined analysis. The limiting factor, however, remains that those experimental replicates also require more sample DNA. To determine the statistical power of both the classic and SNP-based approach

265 in our application of analysing samples with diverse total and melanoma-cell derived vfDNA 266 concentrations, we performed *in silico* simulations based on the initial $G\alpha_{d}$ mutant and wild-267 type measurements of all vfDNA+/UM+ samples. For each individual sample, we evaluated 268 the sensitivity of detecting a chromosomal loss (copy number = 1) or gain (copy number = 3) 269 assuming that this alteration is clonally present in the vfDNA melanoma-cell population. As 270 representative examples, the *in silico* analyses and *in vitro* observations for measuring 271 chromosome 3p loss in samples vfDNA-41 and vfDNA-24 are presented in Figure 5B and C. 272 A summary of the analyses for all samples is given in **Supplementary Table 1**. 273 274 Some vfDNA samples were found to contain sufficient amounts of DNA to detect a

275 chromosomal alteration in a single digital PCR experiment (such as vfDNA-41 in Figure 5B). 276 In other samples, the sensitivity of detecting a CNA was lower, but this could be increased by 277 repeating the experiment up to three times and merging the results (such as vfDNA-24 in 278 Figure 5C). In general, higher levels of sensitivity were obtained when more droplets could 279 be analysed, when more melanoma-cell derived vfDNA was present and when less healthy 280 cell DNA 'contaminated' the sample (Supplementary Table 1). Moreover, in line with our 281 earlier observations [19, 20], the SNP-based approach was generally more precise than the 282 classic alternative (Figure 5C) and was chosen as preferred methodology whenever 283 available.

284

285 Based on the *in silico* results, we limited further copy number analysis to those vitreous fluid 286 samples with an expected sensitivity >80% of calling a loss (of chromosome 3p, in 21/39 = 287 54% of the vfDNA+/UM+ samples) or gain (of chromosome 8q, in 20/39 = 51% of the 288 vfDNA+/UM+ samples) in the available amount of vfDNA (Materials and methods and 289 Figure 2). Within this subgroup, chromosome 3p losses were detected in 13/15 samples with 290 a known loss in the matched primary tumour. Similarly, chromosome 8q copy number 291 increases were detected in 15/17 samples with a known chromosome 8q CNA in the tumour. 292 It is noteworthy that in all four discordant cases, the CNA (that remained undetected in the 293 vfDNA) was heterogeneously present in the matched primary tumour; two uveal melanomas 294 had a subclonal loss of chromosome 3p and two a subclonal gain of chromosome 8g 295 (Supplementary Table 1) [20]. We did not detect CNAs in vfDNA+/UM+ samples with no 296 chromosome 3p (n=6) or 8q (n=3) alterations in the matched primary tumour, nor in a 297 selection of underpowered vfDNA+/UM+ samples and vfDNA+/UM- samples (which lack 298 copy number altered melanoma-cell derived DNA). Overall, the presence of chromosome 3p 299 and 8g alterations matched those in the primary tumour in 19/21 (90%) and 18/20 (90%) 300 analysable vitreous fluid samples, respectively.

301

302 Clinicopathological context

303 Lastly, we investigated whether the vfDNA content correlated to the clinicopathological 304 context of the primary tumour. First of all, we hypothesised that the detectability of 305 melanoma-cell derived vfDNA related to anatomical characteristics of the primary tumour 306 (Figure 6A and B). No significant differences were found with regard to the largest basal 307 diameter and frequency tumours broken through Bruch's membrane, but patients with 308 melanoma-cell derived vfDNA had a larger prominence of their primary tumour (median 8 309 versus 6 mm, Mann-Whitney U p = 0.018) than those without. Within the vfDNA+/UM+ 310 samples, there was a significant positive correlation between the prominence of primary 311 tumour and concentration of melanoma-cell derived vfDNA (Spearman's rho = 0.52, p < 312 0.001, Figure 6C). 313

- Based on the genetic analysis of the primary tumours [20], the distribution of the various
- 315 molecular uveal melanoma subtypes within the vfDNA+/UM- and vfDNA+/UM+ patients was
- found to be very similar (Figure 6D and Supplementary Table 1). Not unexpectedly, the
- 317 absence or presence of melanoma-cell derived vfDNA itself did not show an association with
- 318 melanoma-related survival (Figure 6E). Focussing on the subsequent vfDNA measurements,
- 319 however, the molecular subtype of the primary tumour could be successfully inferred from
- 320 27/65 (42%) of the vfDNA samples. Within this subgroup, the prognostic relevance of the
- molecular classification was evident (log-rank p = 0.020, Figure 6F): patients with a BAP1
- 322 mutation and/or monosomy 3p had a median melanoma-related survival of 5.8 years, while
- the estimated median survival was not reached in the group of patients with an *EIF1AX*
- 324 mutation, *SF3B1* mutation and/or disomy 3p.

325 **Discussion**

326 In various malignancies, the analysis of liquid biopsies has proven to provide clinically-

327 relevant molecular information of primary or metastatic tumours, while forming a less

invasive alternative to direct tumour biopsies [21, 29]. In ocular oncology, the genetic

329 analysis of eye fluids has a prominent role in the differentiation between a malignant intra-

330 ocular lymphoma and a benign uveitis [30], but it remained unexplored in the context of

331 characterising uveal melanoma. For this reason, we investigated the DNA from the vitreous

fluid as a potential source of molecular information from the primary tumour (**Figure 1**).

333

334 Firstly, we measured the total amount and fraction of melanoma-cell derived vfDNA based on 335 the abundance of mutant and wild-type $G\alpha_q$ alleles (**Figure 2 and 3**). This analysis was successful in 97% of the samples, indicating that nearly all vitreous fluids contained 336 337 measurable levels of DNA. However, in only 60% of all samples part of this genetic material 338 was derived from melanoma cells. This indicates that a considerable proportion of the DNA 339 present in the vitreous originated from non-malignant cells. It would be interesting to further 340 characterise the cell type of origin of this DNA, for example by applying genetic immune cell 341 measurements or epigenetic profiling [31-34].

342

343 Next, we tested the vfDNA+/UM+ samples for additional DNA alterations. Based on the 344 known genetic profile of the matched primary tumour, 13/15 (87%) of the analysed vitreous 345 fluid samples had a measurable BSE mutation (Figure 2 and 4). Importantly, however, this 346 supervised mutational screening is not feasible when no matched tumour material is 347 available. In such situations, the vfDNA should be screened for all possible alterations, but 348 this procedure requires multiple experiments and is sample-expensive. A possible solution 349 may be found in the development of multiplex setups in which various assays are combined 350 within one experiment. Our EIF1AX drop-off assays furthermore proved that mutation 351 analyses can be made more generic: all different exon 1 and 2 mutations could be measured 352 requiring only two distinct assays. Similar drop-off approaches may be developed for the $G\alpha_{d}$ 353 signalling mutations and the majority of SF3B1 mutations. However, it is unlikely that 354 comparable assays can be developed to generically detect all BAP1 mutations, as these 355 mutations do no occur at hotspot positions and are practically unique in each mutant tumour. 356

In addition to the BSE mutations, CNAs were studied in the vfDNA+/UM+ samples. The
presence of chromosome 3p and 8q alterations corresponded with those in the primary
tumour in 19/21 (90%) and 18/20 (90%) of the analysable cases, respectively (Figure 2 and

5). Though, we noted that remarkable differences exist in the detectability of melanoma-cell

361 derived mutations versus CNAs: whereas the qualitative identification of any mutant allele 362 inevitably confirms the presence of this mutation, a CNA can only be detected upon a precise 363 guantification of the chromosomal target in comparison to the healthy copy number invariant 364 situation. This leads to sample-specific detection limits that are higher than those for 365 mutations, especially in samples with large amounts of 'contaminating' non-melanoma cell 366 derived unaltered DNA. In this study, we first evaluated the detectability of CNAs in silico, 367 based on the varying concentrations of (non-)melanoma-cell derived DNA of each individual 368 sample (Figure 5). As a result, roughly half of the vfDNA+/UM+ samples were found to have 369 a too low total DNA concentration or fraction melanoma-cell derived DNA, and were 370 technically underpowered to detect chromosomal gains or losses. While this means that no 371 conclusions can be drawn on the presence of CNAs in these samples, this in silico analysis 372 helped to avoid generating false-negative results and prevented an unnecessary waste of 373 precious material.

374

375 Although most of our vfDNA analyses successfully identified the BSE mutation or CNA 376 present in the primary tumour, a number of cases was discordant (Figure 2 and 377 **Supplementary Table 1**). We noted that the two BSE-lacking vitreous fluid samples 378 presented extreme low purity (< 0.8 G α_{α} mutant copies/uL), which may challenge the 379 identification of additional mutations with alternative assays. It would be interesting to further 380 compare all digital PCR mutation assays for their exact lower limits of detection, and to 381 repeat experiments to exclude vfDNA subsampling and improve the sensitivity of the 382 mutation detection. In contrast, the four CNA-lacking vitreous fluid samples were predicted to 383 have sufficient melanoma-cell derived DNA concentrations to detect chromosomal gains and 384 losses, assuming that the alteration clonally abundant in the entire melanoma-cell derived 385 fraction vfDNA. Intriguingly, all CNA-discordant cases demonstrated heterogeneity for this 386 chromosomal loss or gain in the primary tumour. This admixed presence of clones with and 387 without a certain alteration may explain why it could not be detected in the vitreous fluid: it 388 may be not present or only present in an undetectable low proportion in the fraction 389 melanoma-cell derived vfDNA.

390

From a clinical perspective, we found that the detectability of melanoma-cell derived vfDNA was associated with a higher amount of non-tumour cell derived vfDNA and a larger prominence of the primary tumour (Figure 6A and C). This suggests that larger (and possibly more invasive) growth of uveal melanomas contributes to the presence of DNA in the vitreous fluid, originating from both melanoma and other cells. However, the identification of melanoma-cell derived vfDNA itself did not mark a genetically distinct or prognosticallyrelevant subgroup of patients (Figure 6D and E). By combining the BSE mutation and CNA

results, in 27/65 (42%) of the cases the molecular subtype of the primary tumour could be
successfully inferred from the vfDNA measurements. Within this subgroup, the correlation
between this molecular classification of tumours and patients' risk of developing lethal
metastases was clearly demonstrated (Figure 6F).

402

403 Our findings illustrate that in a proportion of patients, relevant molecular information from 404 their primary uveal melanoma may be derived from analysing the DNA present in the 405 vitreous fluid. Following this approach, the risk of metastatic tumour dissemination may be 406 estimated without a direct tumour biopsy, and an increasing number of patients may be 407 offered concordant clinical follow-up. Nevertheless, it is crucial to note that in our current 408 study the vitreous fluid samples were investigated that had been collected ex vivo from 409 enucleated eyes. This procedure is different to it would be in a clinical setting, and uveal 410 melanomas treated by enucleation are typically larger and more invasive than irradiated 411 tumours. Therefore, a follow-up study should evaluate the applicability of our methodology in 412 a prospective clinical context, for example by defining patient groups most likely to benefit 413 from the analysis (e.g. those with relatively thick tumours), and by evaluating vfDNA collected 414 in a similar way as performed in vivo from non-enucleated eyes.

415

416 One may also consider to explore possible additions and alternatives to our current

- 417 methodologies. For example, epigenetic targets (such as DNA methylation) may be
- 418 evaluated as markers for the various molecular subtypes of uveal melanomas. Candidate loci
- 419 have already been identified [35, 36], and as DNA methylation can be measured using digital
- 420 PCR as well [37, 38], the analysis may be easily incorporated in our current workflow.
- 421 Additionally, the experimental performance might be optimised to reach lower limits of
- 422 detection, for example by denaturating the DNA samples prior to digital PCR analysis [39].
- 423 As further alternatives, vitreous fluid samples may be studied using complementary
- 424 molecular techniques (such as ultradeep sequencing) or by analysing its RNA, as we
- recently showed that tumour-derived genetic information may also be inferred from a
- 426 transcriptional level [40].
- 427
- Lastly, we believe that our digital PCR assays and approaches have translational potential in
- 429 the analysis of heterogeneous solid or liquid uveal melanoma biopsies of any other origin.
- 430 Some of the mutation assays described in this study have already been used in blood-based
- 431 screening of uveal melanoma patients [41], and the value of similar applications is
- 432 increasingly recognised [42].
- 433

- 434 In conclusion, our findings demonstrate the possibility of capturing the molecular profile of a
- 435 primary uveal melanoma by analysing the DNA present in the vitreous fluid of the eye. As
- this approach does not require a biopsy to be taken from the tumour itself, a molecular
- 437 classification of the primary tumour and concordant follow-up might be offered to more
- 438 patients. In the end, this may ameliorate the clinical outcome of patients with this aggressive
- 439 malignancy.

440 **Figures**

441 Figure 1



- 444 Workflow of current study: DNA from primary tumours [20] and vitreous fluid samples in 65
- 445 enucleated eyes is analysed by digital PCR.

446 Figure 2



447

448 DNA composition and detectability of molecular alterations in 65 vitreous fluid samples.

449 Mutations and CNAs are compared to those identified in the matched primary tumour [20],

450 and their detection in the vfDNA is visualised. 'No assay' refers to a selection of mutations

451 that were known to be present in the primary tumour, but could not be analysed in the vfDNA

452 sample. 'Underpowered' refers to the condition in which the amount of total and melanoma-

453 cell derived vfDNA was predicted to be insufficient to detect chromosomal CNAs.

454 Figure 3



455

456 (A) Analysis of $G\alpha_q$ signalling mutations using targeted digital PCR, here exemplified for the

457 measurement of *GNA11* p.Q209L mutant and wild-type DNA alleles with two representative

458 2D plots for a vfDNA+/UM- and vfDNA+/UM+ sample.

459 (B) Comparison of non-melanoma cell-derived DNA concentrations in vfDNA+/UM- and

460 vfDNA+/UM+ samples.

461 **Figure 4**



462

463

- 464 Analysis of BSE mutations in EIF1AX (A), SF3B1 (B) and BAP1 (C) using drop-off and
- targeted digital PCR assays. Here exemplified with the representative 2D plots for a wild-type
- 466 and mutant vfDNA sample with similar total vfDNA concentrations.

All rights reserved. No reuse allowed without permission.

467 Figure 5



- 468 469
- 470 (A) Approaches to analyse copy number alterations, here exemplified for measuring
- 471 chromosome 3p loss.
- 472 (B) Simulated and observed copy number value measurements for chromosome 3p in
- 473 vfDNA-41, with associated confidence intervals. Simulations were based on the initial $G\alpha_q$
- 474 mutant and wild-type measurements and the assumption of a clonal loss in the vfDNA
- 475 melanoma-cell population, in single experiments using both the classic and SNP-based
- 476 approach. Significance of the measurements is indicated by the colour of the individual
- 477 confidence interval (red: not significantly different from 2 [*p* > 0.01], grey: significantly
- 478 different from 2 [p < 0.01]).
- 479 (C) Overview of simulated and observed copy number value measurements for chromosome
- 480 3p in vfDNA-24, in both single and (3x) merged experiments using the SNP-based approach.

481 Figure 6



482 483

484 (A) Comparison in pathologically-determined largest basal diameter and prominence of

485 matched primary tumours in vfDNA+/UM- or UM+ samples. The black horizontal line

486 denotes the median value for both groups.

487 (B) Comparison in frequency of pathologically-determined breaching of Bruch's membrane in

488 matched primary tumours in vfDNA+/UM+ and UM- samples.

489 (C) Correlation between concentrations of mutant vfDNA and pathologically-determined

490 prominence of matched primary tumours in vfDNA+/UM+ samples.

491 (**D**) Comparison in frequency of matched primary tumours with a poor prognostic molecular

492 subtype (*BAP1* mutation and/or monosomy 3p) in vfDNA+/UM- or UM+ samples.

493 (E) Melanoma-related survival of patients within the vfDNA+/UM- or UM+ groups.

494 (F) Melanoma-related survival of patients based on the inferred molecular subtypes from

495 vfDNA measurements.

All rights reserved. No reuse allowed without permission.

496 **References**

- 497 1. Jager, M.J., et al., *Uveal melanoma*. Nat Rev Dis Primers, 2020. **6**(1): p. 24.
- 498 2. Eskelin, S., et al., *Tumor doubling times in metastatic malignant melanoma of the*499 *uvea: tumor progression before and after treatment.* Ophthalmology, 2000. **107**(8): p.
 500 1443-9.
- 5013.Uner, O.E., et al., Estimation of the timing of BAP1 mutation in uveal melanoma502progression. Sci Rep, 2021. 11(1): p. 8923.
- 5034.Martin, M., et al., Exome sequencing identifies recurrent somatic mutations in EIF1AX504and SF3B1 in uveal melanoma with disomy 3. Nat Genet, 2013. 45(8): p. 933-6.
- 505 5. Rodrigues, M., et al., *Evolutionary Routes in Metastatic Uveal Melanomas Depend on* 506 *MBD4 Alterations.* Clin Cancer Res, 2019. **25**(18): p. 5513-5524.
- 507 6. Furney, S.J., et al., *SF3B1 mutations are associated with alternative splicing in uveal* 508 *melanoma.* Cancer Discov, 2013. **3**(10): p. 1122-1129.
- 5097.Harbour, J.W., et al., Recurrent mutations at codon 625 of the splicing factor SF3B1510in uveal melanoma. Nat Genet, 2013. 45(2): p. 133-5.
- Yavuzyigitoglu, S., et al., Uveal Melanomas with SF3B1 Mutations: A Distinct
 Subclass Associated with Late-Onset Metastases. Ophthalmology, 2016. 123(5): p.
 1118-28.
- 514 9. Harbour, J.W., et al., *Frequent mutation of BAP1 in metastasizing uveal melanomas.*515 Science, 2010. **330**(6009): p. 1410-3.
- 51610.Robertson, A.G., et al., Integrative Analysis Identifies Four Molecular and Clinical517Subsets in Uveal Melanoma. Cancer Cell, 2017. **32**(2): p. 204-220 e15.
- 518 11. Singh, A.D., et al., *Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications.* Br J Ophthalmol, 2016. **100**(4): p. 456-62.
- 520 12. Sellam, A., et al., *Fine Needle Aspiration Biopsy in Uveal Melanoma: Technique,* 521 *Complications, and Outcomes.* Am J Ophthalmol, 2016. **162**: p. 28-34 e1.
- Lieb, M., et al., *Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study.* BMC Psychol, 2020.
 8(1): p. 8.
- 525 14. Damato, B.E., et al., *Tebentafusp: T Cell Redirection for the Treatment of Metastatic* 526 *Uveal Melanoma.* Cancers (Basel), 2019. **11**(7).
- 527 15. Bigot, J., et al., Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate
 528 Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov, 2021. 11(8): p.
 529 1938-1951.
- 53016.Versluis, M., et al., Digital PCR validates 8q dosage as prognostic tool in uveal531melanoma. PLoS One, 2015. **10**(3): p. e0116371.
- 532 17. de Lange, M.J., et al., *Heterogeneity revealed by integrated genomic analysis*533 *uncovers a molecular switch in malignant uveal melanoma*. Oncotarget, 2015. 6(35):
 534 p. 37824-35.
- 53518.Nell, R.J., et al., Involvement of mutant and wild-type CYSLTR2 in the development536and progression of uveal nevi and melanoma. BMC Cancer, 2021. 21(1): p. 164.
- Nell, R.J., et al., Allele-specific digital PCR enhances precision and sensitivity in the
 detection and quantification of copy number alterations in heterogeneous DNA
 samples: an in silico and in vitro validation study. medRxiv, 2023.
- 540 20. Nell, R.J., et al., *Digital PCR-based deep quantitative profiling delineates* 541 *heterogeneity and evolution of uveal melanoma.* medRxiv, 2024.
- 542 21. Olmedillas-Lopez, S., M. Garcia-Arranz, and D. Garcia-Olmo, *Current and Emerging*543 *Applications of Droplet Digital PCR in Oncology.* Mol Diagn Ther, 2017. 21(5): p. 493544 510.
- Zoutman, W.H., R.J. Nell, and P.A. van der Velden, Usage of Droplet Digital PCR
 (ddPCR) Assays for T Cell Quantification in Cancer. Methods Mol Biol, 2019. 1884: p.
 1-14.

548 23. Van Raamsdonk, C.D., et al., Frequent somatic mutations of GNAQ in uveal 549 melanoma and blue naevi. Nature, 2009. 457(7229): p. 599-602. Van Raamsdonk, C.D., et al., Mutations in GNA11 in uveal melanoma. N Engl J Med, 550 24. 551 2010. **363**(23): p. 2191-9. 552 25. Johansson, P., et al., Deep sequencing of uveal melanoma identifies a recurrent 553 mutation in PLCB4. Oncotarget, 2016. 7(4): p. 4624-31. 554 26. Moore, A.R., et al., Recurrent activating mutations of G-protein-coupled receptor 555 CYSLTR2 in uveal melanoma. Nat Genet, 2016. 48(6): p. 675-80. 556 27. Vader, M.J.C., et al., GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br J Cancer, 2017. 117(6): p. 884-887. 557 28. 558 Durante, M.A., et al., Genomic evolution of uveal melanoma arising in ocular 559 melanocytosis. Cold Spring Harb Mol Case Stud, 2019. 5(4). 29. 560 Lone, S.N., et al., Liquid biopsy: a step closer to transform diagnosis, prognosis and 561 future of cancer treatments. Mol Cancer, 2022. 21(1): p. 79. 562 30. de Hoog, J., et al., Combined cellular and soluble mediator analysis for improved 563 diagnosis of vitreoretinal lymphoma. Acta Ophthalmol, 2019. 97(6): p. 626-632. 564 31. Zoutman, W.H., et al., Accurate Quantification of T Cells by Measuring Loss of 565 Germline T-Cell Receptor Loci with Generic Single Duplex Droplet Digital PCR 566 Assays. J Mol Diagn, 2017. **19**(2): p. 236-243. 567 32. de Lange, M.J., et al., Digital PCR-Based T-cell Quantification-Assisted 568 Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive 569 Tumor Inflammation in Uveal Melanoma. Mol Cancer Res, 2018. 16(12): p. 1902-570 1911. 571 33. Zoutman, W.H., et al., A novel digital PCR-based method to quantify (switched) B 572 cells reveals the extent of allelic involvement in different recombination processes in 573 the IGH locus. Mol Immunol, 2022. 145: p. 109-123. 574 34. van de Leemkolk, F.E.M., et al., Quantification of Unmethylated Insulin DNA Using 575 Methylation Sensitive Restriction Enzyme Digital Polymerase Chain Reaction. 576 Transpl Int, 2022. **35**: p. 10167. 577 35. Field, M.G., et al., BAP1 Loss Is Associated with DNA Methylomic Repatterning in 578 Highly Aggressive Class 2 Uveal Melanomas. Clin Cancer Res, 2019. 25(18): p. 579 5663-5673. 580 36. Bakhoum, M.F., et al., BAP1 methylation: a prognostic marker of uveal melanoma 581 metastasis. NPJ Precis Oncol, 2021. 5(1): p. 89. 582 37. Nell, R.J., et al., Quantification of DNA methylation independent of sodium bisulfite 583 conversion using methylation-sensitive restriction enzymes and digital PCR. Hum 584 Mutat, 2020. 41(12): p. 2205-2216. 585 38. Salgado, C., et al., Interplay between TERT promoter mutations and methylation 586 culminates in chromatin accessibility and TERT expression. PLoS One, 2020. 15(4): 587 p. e0231418. Fitarelli-Kiehl, M., et al., Denaturation-Enhanced Droplet Digital PCR for Liquid 588 39. 589 Biopsies. Clin Chem, 2018. 64(12): p. 1762-1771. 590 40. Nell, R.J., et al., Identification of clinically-relevant genetic alterations in uveal 591 melanoma using RNA sequencing. medRxiv, 2023. 592 41. Beasley, A., et al., Clinical Application of Circulating Tumor Cells and Circulating 593 Tumor DNA in Uveal Melanoma. JCO Precis Oncol, 2018. 2. 594 42. Carvajal, R.D., et al., Clinical and molecular response to tebentafusp in previously 595 treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med, 2022. 596 **28**(11): p. 2364-2373. 597

Supplementary information 598

Supplementary Table 1 599

600 Overview of clinical and molecular information of all cases analysed in this study.